UPDATE 1-FDA declines to approve re-launch of ADMA Biologics' Bivigam

The U.S. Food and Drug Administration (FDA)on Wednesday declined to approve ADMA Biologics Inc's application to re-launch its immune deficiency treatment Bivigam, the company said.